Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Transitioning patients from an originator to a corresponding biosimilar has been extensively studied in both randomized controlled trials and observational studies. Although transitioning is considered well-tolerated, with no negative impacts on efficacy and/or safety, 2.6-25.8% of patients restart treatment with the originator (retransitioning). Retransitioning to the originator can be considered an indication of biosimilar treatment failure or dissatisfaction with biosimilar treatment. Increasing our knowledge of patients who retransition might help to reduce the number of patients retransitioning. OBJECTIVE: Our objective was to estimate the cumulative incidence of patients who retransitioned from a tumor necrosis factor (TNF)-α inhibitor biosimilar to originator and to explore potential patient, disease, and treatment and implementation strategy factors associated with retransitioning. METHOD: We conducted a systematic literature search in the PubMed, EMBASE, and Cochrane Central Register of controlled trials databases until March 2021. Studies on TNFα inhibitors, biosimilar transitioning, and retransitioning were included. Transitioning was defined as switching from an originator to a biosimilar, and retransitioning was defined as switching from an originator to a biosimilar and back to the originator. Characteristics of the studies were descriptively analyzed. Studies were weighted by the number of patients transitioning, and the primary outcome was the median cumulative incidence of retransitioning. For each of the factors related to patient, disease, and treatment and implementation strategy, studies were stratified according to the categories of that factor. The weighted medians and interquartile ranges (IQRs) of the cumulative incidence of retransitioning in these studies were calculated and compared to explore whether a potential association existed between these factors and the cumulative incidence of retransitioning. RESULTS: Of 994 screened publications, 37 were included. The weighted median cumulative incidence of retransitioning was 7.6% (IQR 6.8-17.2). Studies that included only patients with inflammatory bowel disease (6.6 vs. 15.1-17.7% for other indications), included only patients with stable disease (7.0 vs. 13.7% for including all patients), and did not offer retransitioning at the introduction of the biosimilar (7.0 vs. 11.1% for studies that offered retransitioning) reported less retransitioning. In addition, the incidence of retransitioning was lower when extra laboratory monitoring was part of the implementation strategy (1.6 vs. 6.1%) and when gainsharing (patients' healthcare directly benefits from financial savings from transitioning) (1.4 vs. 7.2% for studies without gainsharing) was applied. CONCLUSIONS: In studies on transitioning patients from TNFα originator to biosimilar, 8% of patients retransitioned. Retransitioning appeared to be lower in studies that included only patients with stable disease and in studies that did not offer patients the option of retransitioning at the introduction of the biosimilar. In addition, retransitioning appeared to be lower in studies that implemented extra laboratory monitoring as part of the biosimilar implementation strategy. Clinicians should consider implementing these suggestions as they might reduce retransitioning rates and improve the introduction of biosimilars in clinical practice. PROSPERO registration ID: CRD42021226381.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“we used human researcher-extracted data as the gold standard from four systematic reviews or meta-analyses that had already been published [16–19].”
From Accelerating the pace and accuracy of systematic reviews using AI: a validation study (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Michie, S., van Stralen, M. M., & West, R. (2011) · Implementation Science · doi:10.1186/1748-5908-6-42 · Cited by 13,697
Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J. O., Peyrin-Biroulet, L., Cullen, G. J., Daperno, M., Kucharzik, T., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw168 · Cited by 2,057
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Jørgensen, K. K., Olsen, I. C., Goll, G. L., Lorentzen, M., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Mørk, C., Jahnsen, J., Kvien, T. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30068-5 · Cited by 818
Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
Research works printed but not linked: 8
- European Medicines Agency. Product Information Benepali (etanercept); 2019. pp. 167–72. https://doi.org/10.2307/j.ctvdf0dxq.12. · DOI
- Imraldi. Summary of product characteristics. EMA. 2019;2019:167–72. https://doi.org/10.2307/j.ctvdf0dxq.12. · DOI
- Xue L, et al. Are patients at risk for recurrent disease activity after switching from remicade(®) to Remsima(®)? An observational study. Front Med. 2020;7:418. https://doi.org/10.3389/fmed.2020.00418. · DOI
- Jackson C, Eliasson L, Barber N, Weinman J. Applying COM-B to medication adherence work tended to focus on the role and its effects on patient. Eur Heal Psychol. 2014;16(1):7–17.
- Chan A, Kitchen J, Scott A, Pollock D, Marshall R, Herdman L. Implementing and delivering a successful biosimilar switch programme—the Berkshire West experience. Futur Healthcare J. 2019;6(2):143–5. https://doi.org/10.7861/futurehosp.6-2-143. · DOI
- Deaner JD, et al. Recurrence rates of inflammation after switching from the originator infliximab to biosimilar infliximab-abda for noninfectious uveitis. Am J Ophthalmol. 2020. https://doi.org/10.1016/j.ajo.2020.08.005. · DOI
- Müskens WD, Rongen-van-Dartel SAA, Teerenstra S, Adang EMM, van Riel PLCM. One-year results after transitioning from etanercept originator to biosimilar in a shared decision-making promoting setting in rheumatology. Rheumatol Adv Pract. 2020;1–7:2020. https://doi.org/10.1093/rap/rkaa042. · DOI
- Scherlinger M, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Jt Bone Spine. 2018;85(5):561–7. https://doi.org/10.1016/j.jbspin.2017.10.003. · DOI
Cited by
Dennstädt, F., Zink, J., Putora, P. M., Hastings, J., & Cihoric, N. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02575-4 · Cited by 145
Jourdain, H., Hoisnard, L., Sbidian, É., & Zureik, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-24050-7 · Cited by 16
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Car, E., Vandenplas, Y., Lacosta, T. B., Simoens, S., Huys, I., Vulto, A. G., & Barbier, L. (2024) · Pharmaceutical Medicine · doi:10.1007/s40290-024-00541-y · Cited by 18
Accelerating the pace and accuracy of systematic reviews using AI: a validation study
Zhan, J., Suvada, K., Xu, M., Tian, W., Cara, K. C., Wallace, T. C., & Ali, M. K. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02997-8 · Cited by 12
“The fourth validation dataset (Meijboom et al., 2022) was from a systematic review of RCTs and observational studies related to the incidence of outcomes of patients with cancer who transitioned from one cancer drug to another versus patients who did not transition drugs [19].”
Pellegrini, G., Spini, A., Bellitto, C., L’Abbate, L., Ingrasciotta, Y., Soardo, F., Leoni, O., Mazzone, A., Ancona, D., Stella, P., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251378080 · Cited by 5
Metadata
- Authors
- Meijboom, R. W., Gardarsdottir, H., Egberts, T. C. G., & Giezen, T. J.
- Affiliations
- Utrecht University (NL)
- Corresponding author
- Giezen, Thijs J.
- Venue
- BioDrugs
- Published
- 2021-12-06
- Volume
- 36
- Issue
- 1
- Pages
- 27-39
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- PMC
- PMC8847209
- OpenAlex
- W4200279042
- Cited by
- 18
- References
- 74
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 3
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- BioDrugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- TNF-alpha inhibitors, biosimilar switching, brand-name drugs, inflammatory bowel disease, cumulative incidence, risk factors, laboratory monitoring, patient satisfaction, treatment failure, implementation strategies, stable disease
- MeSH terms
- Infliximab, Humans, Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases, Incidence, Biosimilar Pharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. https://app.cochat.ai/papers/10.1007/s40259-021-00508-4
- The paper
- Meijboom, R. W., Gardarsdottir, H., Egberts, T. C. G., & Giezen, T. J. (2022). Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs. https://doi.org/10.1007/s40259-021-00508-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

